Work

Medicaid Coverage and Utilization for Novel Therapies for Chronic Rhinosinusitis With Nasal Polyposis

Year: 2026

Type: article

Abstract: KEY POINTS: Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.

Source: International Forum of Allergy & Rhinology

DOI: 10.1002/alr.70109

Authors: Eric R. Ramos, Sriram Satyavolu, Ashley L. Miller, George A. Scangas, Zachary M. Soler, Rodney J. Schlosser, Yufan Lin, Vinay K. Rathi

Institutions: The Ohio State University, Nationwide Children's Hospital, Massachusetts Eye and Ear Infirmary, Medical University of South Carolina, Ralph H. Johnson VA Medical Center

Language: English

Topic: Sinusitis and nasal conditions

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,100

OpenAlex ID: W7125489405

FWCI: 14.17

Cites: 9

Cited by: 2

Related to: